Bile acid sequestrants as a therapeutic option for glucose lowering in type 2 diabetes mellitus

Endocrine Practice

Volumn 14, Issue 5, 2008, Pages 644-647

  Levy, Philip ^a  

^a Phoenix Endocrinology Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; BILE ACID SEQUESTRANT; CHOLESTEROL; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; FARNESOID X RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA DERIVATIVE; ALLYLAMINE; ANTILIPEMIC AGENT; BILE ACID; DRUG DERIVATIVE;

DIABETIC PATIENT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; TREATMENT OUTCOME; ARTICLE; BLOOD; METABOLISM;

ALLYLAMINE; ANTILIPEMIC AGENTS; BILE ACIDS AND SALTS; BLOOD GLUCOSE; CHOLESTYRAMINE; COLESTIPOL; DIABETES MELLITUS, TYPE 2; HUMANS;

EID: 58149468465     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.14.5.644     Document Type: Note

References (18)

1. Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J. 2006;99:257-273.
2. Welchol tablets (colesevelam hydrochloride): highlights of prescribing information. http://www.welchol.com/pdf/Welchol-PI.pdf. Accessed for verification June 4, 2008.
3. Bandisode MS, Boshell BR. Hypocholesterolemic activity of colestipol in diabetes. Curr Ther Res Clin Exp. 1975;18:276-284.
4. Düntsch G. Colestipol by hypercholesteremia in diabetics [article in German]. Fortschr Med. 1977;95:1492-1496.
5. Tonolo G, Melis MG, Formato M, et al. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest. 2000;30:980-987.
6. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus: a short-term, double-blind, crossover trial. Ann Intern Med. 1994;121:416-422.
7. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the Glucose-Lowering Effect of WelChol Study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther. 2007;29:74-83.
8. Bays HE, Cohen DE. Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2007;23:1673-1684.
9. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam HCl in diabetes patients treated with met-formin: glucose and lipid effects. Arch Intern Med. 2008. In press.
10. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL-cholesterol in patients with type 2 diabetes inadequately controlled on sulfonylurea-based therapy [published online ahead of print May 5, 2008]. Diabetes Care. doi:10.2337/dc08-0283.
11. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008. In press.
12. Inoue Y, Yu AM, Yim SH, et al. Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4alpha. J Lipid Res. 2006;47:215-227.
13. Zhang M, Chiang JY. Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (CYP8B1): roles of hepatocyte nuclear factor 4alpha in mediating bile acid repression. J Biol Chem. 2001;276:41690-41699.
14. Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology. 2002;143:1741-1747.
15. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology. 2004;145:2594-2603.
16. Duran-Sandoval D, Mautino G, Martin G, et al. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes. 2004;53:890-898.
17. Mitro N, Mak PA, Vargas L, et al. The nuclear receptor LXR is a glucose sensor. Nature. 2007;445:219-223.
18. Jellinger PS, Davidson JA, Blonde L, et al (ACE/AACE Diabetes Road Map Task Force). Road maps to achieve glycemic control in type 2 diabetes mellitus. Endocr Pract. 2007;13:260-268.